CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
-20.86%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$711M
AUM Growth
+$711M
(-29%)
Cap. Flow
-$72M
Cap. Flow
% of AUM
-10.13%
Top 10 Holdings %
Top 10 Hldgs %
83.62%
Holding
33
New
5
Increased
15
Reduced
7
Closed
4
Top Buys
| 1 |
Vanda Pharmaceuticals
VNDA
|
$16.2M |
| 2 |
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
|
$15.9M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$12.6M |
| 4 |
AbbVie
ABBV
|
$8M |
| 5 |
INSY
Insys Therapeutics, Inc.
INSY
|
$7.77M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$67.4M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$24.2M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$23.7M |
| 4 |
Celldex Therapeutics
CLDX
|
$19M |
| 5 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
$12.1M |
Sector Composition
| 1 | Healthcare | 84.53% |
| 2 | Technology | 0.52% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $100M | 14.1% | 1,353,913 +170,507 | +14% | +$12.6M |
|
|
INSY
2
DELISTED
Insys Therapeutics, Inc.
INSY
| $92.7M | 13.04% | 3,257,094 +273,000 | +9% | +$7.77M |
|
|
3
AbbVie
ABBV
$372B
| $78.7M | 11.07% | 1,445,900 +147,000 | +11% | +$8M |
|
4
Travere Therapeutics
TVTX
$1.56B
| $69.9M | 9.84% | 3,450,323 +50,000 | +1% | +$1.01M |
|
5
Orthofix Medical
OFIX
$592M
| $60.3M | 8.48% | 1,786,535 +60,838 | +4% | +$2.05M |
|
|
AKRX
6
DELISTED
Akorn, Inc.
AKRX
| $53.4M | 7.52% | 1,873,756 +30,000 | +2% | +$855K |
|
7
ANI Pharmaceuticals
ANIP
$2.03B
| $41.7M | 5.87% | 1,056,289 +498 | +0% | +$19.7K |
|
|
OSIR
8
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $37.6M | 5.29% | 2,035,709 +859,514 | +73% | +$15.9M |
|
|
CSII
9
DELISTED
Cardiovascular Systems, Inc.
CSII
| $36.9M | 5.19% | 2,326,748 -149,539 | -6% | -$2.37M |
|
10
Pacific Biosciences
PACB
$393M
| $22.9M | 3.22% | 6,257,861 +859,000 | +16% | +$3.14M |
|
|
11
Enanta Pharmaceuticals
ENTA
$180M
| $20.6M | 2.9% | 570,662 -670,659 | -54% | -$24.2M |
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $17.4M | 2.45% | 5,802,885 +285,000 | +5% | +$855K |
|
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $16.2M | 2.28% | +1,436,796 | New | +$16.2M |
|
|
EPRS
14
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $10.3M | 1.45% | 2,324,669 +58,681 | +3% | +$259K |
|
|
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $8.92M | 1.25% | 1,893,467 +132,818 | +8% | +$626K |
|
16
ADMA Biologics
ADMA
$4.12B
| $8.8M | 1.24% | 1,052,142 +17,421 | +2% | +$146K |
|
|
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.19M | 1.01% | 449,325 | – | – |
|
18
Vericel Corp
VCEL
$1.83B
| $6.38M | 0.9% | 2,352,940 | – | – |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.16M | 0.58% | 45,183 -257,948 | -85% | -$23.7M |
|
|
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $4.03M | 0.57% | +248,502 | New | +$4.03M |
|
|
IMPR
21
DELISTED
IMPRIVATA, INC COM
IMPR
| $3.67M | 0.52% | 206,448 +110,689 | +116% | +$1.97M |
|
|
MSLI
22
DELISTED
Merus Labs International Inc.
MSLI
| $1.68M | 0.24% | 1,303,484 -338,104 | -21% | -$436K |
|
23
Lineage Cell Therapeutics
LCTX
$267M
| $1.62M | 0.23% | 539,640 -115,900 | -18% | -$348K |
|
24
Veracyte
VCYT
$2.39B
| $1.25M | 0.18% | 266,794 -32,172 | -11% | -$151K |
|
|
BIOL
25
DELISTED
Biolase, Inc.
BIOL
| $1.04M | 0.15% | 1,154,372 +486,708 | +73% | +$438K |
|